companiesCompany
Blue Earth Diagnostics (Bracco)
Blue Earth Diagnostics makes Posluma (18F-rhPSMA-7.3) and Axumin (fluciclovine) PET agents for prostate cancer.
Blue Earth Diagnostics is a Bracco subsidiary. Posluma approved 2023 (LIGHTHOUSE, SPOTLIGHT trials); rhPSMA therapeutic analogue in development.
ApprovedPET imaging agent
Flotufolastat F-18 · Posluma
Flotufolastat is a third PSMA PET tracer, with a radiohybrid chemistry designed to be reused for therapy.
Not mapped herePET radiotracer (synthetic amino acid)
Fluciclovine F-18 · Axumin
Fluciclovine F-18 was the first PET tracer approved for finding recurrent prostate cancer after treatment (2016), and has been largely superseded since 2020 by PSMA PET.
Pages like this
not linked directly; found by shared links- TermBiochemical recurrence (BCR)
Shares Fluciclovine F-18, Prostate cancer.
- TargetPSMA
Shares Flotufolastat F-18, Prostate cancer.